✦ LIBER ✦

Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial

✍ Scribed by Araujo, John C; Trudel, Géralyn C; Saad, Fred; Armstrong, Andrew J; Yu, Evan Y; Bellmunt, Joaquim; Wilding, George; McCaffrey, John; Serrano, Sergio V; Matveev, Vsevolod B; Efstathiou, Eleni; Oudard, Stephane; Morris, Michael J; Sizer, Bruce; Goebell, Peter J; Heidenreich, Axel; de Bono, Johann S; Begbie, Stephen; Hong, Jun H; Richardet, Eduardo; Gallardo, Enrique; Paliwal, Prashni; Durham, Susan; Cheng, Shinta; Logothetis, Christopher J

Book ID: 122224584
Publisher: The Lancet
Year: 2013
Tongue: English
Weight: 703 KB
Volume: 14
Category: Article
ISSN: 1470-2045
DOI: 10.1016/S1470-2045(13)70479-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Aflibercept versus placebo in combinatio

Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial

✍ Tannock, Ian F; Fizazi, Karim; Ivanov, Sergey; Karlsson, Camilla Thellenberg; Fl 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 310 KB

Re: Aflibercept versus Placebo in Combin

Re: Aflibercept versus Placebo in Combination with Docetaxel and Prednisone for Treatment of Men with Metastatic Castration-Resistant Prostate Cancer (VENICE): A Phase 3, Double-Blind Randomised Trial

✍ Taneja, Samir S. 📂 Article 📅 2014 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 59 KB

Randomized, Double-Blind, Placebo-Contro

Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401

✍ Kelly, W. K.; Halabi, S.; Carducci, M.; George, D.; Mahoney, J. F.; Stadler, W. 📂 Article 📅 2012 🏛 American Society of Clinical Oncology 🌐 English ⚖ 190 KB

Docetaxel and atrasentan versus docetaxe

Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial

✍ Quinn, David I; Tangen, Catherine M; Hussain, Maha; Lara, Primo N; Goldkorn, Ami 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 261 KB

Re: Docetaxel and Atrasentan versus Doce

Re: Docetaxel and Atrasentan versus Docetaxel and Placebo for Men with Advanced Castration-Resistant Prostate Cancer (SWOG S0421): A Randomised Phase 3 Trial

✍ Taneja, Samir S. 📂 Article 📅 2014 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 68 KB

Ipilimumab versus placebo after radiothe

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

✍ Kwon, Eugene D; Drake, Charles G; Scher, Howard I; Fizazi, Karim; Bossi, Alberto 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 469 KB